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Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is required for nor-
mal cell growth and development. PP2A is a potent tumor suppressor, which is inactivated
in cancer cells as a result of genetic deletions and mutations. In myeloid leukemias, genes
encoding PP2A subunits are generally intact. Instead, PP2A is functionally inhibited by
post-translational modifications of its catalytic C subunit, and interactions with negative
regulators by its regulatory B and scaffold A subunits. Here, we review the molecular
mechanisms of genetic and functional inactivation of PP2A in human cancers, with a par-
ticular focus on human acute myeloid leukemias (AML). By analyzing expression of genes
encoding PP2A subunits using transcriptome sequencing, we find that PP2A dysregulation
in AML is characterized by silencing and overexpression of distinct A scaffold and B regu-
latory subunits, respectively. We review the mechanisms of functional PP2A activation by
drugs such as fingolimod, forskolin, OP449, and perphenazine.This analysis yields two non-
mutually exclusive mechanisms for therapeutic PP2A re-activation: (i) allosteric activation of
the phosphatase activity, and (ii) stabilization of active holo-enzyme assembly and displace-
ment of negative regulatory factors from A and B subunits. Future studies should allow
the development of specific and potent pharmacologic activators of PP2A, and definition
of susceptible disease subsets based on specific mechanisms of PP2A dysregulation.
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INTRODUCTION
Protein phosphatase 2A (PP2A) is a serine/threonine protein phos-
phatase that is required for normal cell growth and development
and is frequently inactivated in human cancers (1). The functions
of PP2A depend on its regulated phosphatase activities toward spe-
cific substrates, controlling kinase-dependent signal transduction,
protein stability, cell proliferation, and survival (2). The functions
of PP2A as a tumor suppressor in human cancers was originally
defined as a result of its functional inactivation by the direct bind-
ing of the transforming antigens of the SV40 polyoma virus, as well
as inactivating deletions and mutations of genes encoding its enzy-
matic subunits (3). Cells transformed by the polyoma T antigens or
mutations of PP2A subunits exhibit reduced phosphorylation of
PP2A substrates, including key mediators of mitogenic signaling,
apoptosis, and mitosis; reviewed by Sabina et al. (4). Since nor-
mal cell growth and development are incompatible with complete
inactivation of PP2A (5, 6), cell transformation induced by PP2A
inactivation likely involves partial effects on specific substrates.
Specific recruitment of cellular substrates to the phosphatase
catalytic subunit of PP2A is mediated by the assembly of its
trimeric holo-enzyme (7). Active PP2A holo-enzyme is com-
posed of the regulatory B, catalytic C, and scaffold A subunits,
with the AC heterodimer forming the core enzyme (8). There
is large diversity in the types of PP2A holo-enzymes formed,
which is due to the array of genes and isoforms responsible for
PP2A subunits with genetic redundancy of at least two genes
encoding each of the different subunits. This diversity leads to
heterogeneity in subunit isoforms in terms of genetic alterations,
differential tissue expression, and varying types of malignan-
cies. Pharmacological inhibition of PP2A phosphatase activity
by toxins or small molecule drugs, including okadaic acid and
microcystin, causes cellular transformation (9, 10), raising the
possibility that pharmacological re-activation of residual PP2A
activity may have anti-tumor efficacy. Here, we review the molec-
ular mechanisms of PP2A in human cancer, with a specific focus
on myeloid leukemias, and describe pharmacological strategies for
its therapeutic re-activation.
GENETIC MECHANISMS OF PP2A INACTIVATION
Consistent with the requirement of PP2A activity for normal cell
growth and development, genetic inactivation of PP2A appears to
involve deletions and mutations of A or B subunits, but not the
catalytic C subunit. The PP2A holo-enzyme is assembled by the
A scaffold subunit, as structured by its HEAT repeat domain (11).
In this way, the HEAT domain serves to juxtapose the regulatory
B subunits that recruit specific substrates with the catalytic C sub-
unit, as a result of protein–protein interactions of the N-terminal
HEAT repeats 1–10 and C-terminal repeats 11–15 of the scaffold
A subunit, respectively (12). The scaffold subunit A is expressed
as constitutive and tissue-specific isoforms and encoded by differ-
ent genes, PR65α (PPP2R1A) and PR65β (PPP2R1B), respectively
with the PPP2R1B isoform responsible for 5–10% of the scaffold
subunit (13). For example, breast and lung carcinomas inactivate
PP2A by point mutations of thePPP2R1A gene and exon 9 deletion
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in the PPP2R1B genes, allowing for inactivation of PP2A phos-
phatase activity (14). Breast carcinomas also produce defective A
subunits due to the deletions of amino acids 171–589. Similarly,
deletion of E344–E388 that spans HEAT repeats 9 and 10 causes
defective binding of specific regulatory B subunits in breast carci-
nomas. Mutations of the A scaffold PR65α also include mis-sense
mutations E64G in breast carcinomas and R418W in melanomas,
leading to the impaired recruitment of the B regulatory and C cat-
alytic subunits, respectively (15). The PR65β A scaffold isoform
appears to be more frequently affected by mis-sense mutations,
including G8R, P65S, G90D, K343E, D504G, and V545A (16).
Mutants of the PR65α isoform of subunit A have impaired binding
to the B56γ B subunit, induce functional haploinsufficiency and
contribute to cell transformation and near complete suppression
of this Aα isoform leads to growth arrest (17).
In addition to the mutations of the A scaffold subunit, human
cancers also frequently exhibit altered gene expression of the regu-
latory B subunits. For example, thePPP2R2A gene, which codes for
the regulatory subunit B55α, is deleted in breast and prostate car-
cinomas and myelomas (18–20). In melanomas, there is reduced
gene expression of the B56γ subunit encoded by PPP2R5C (21). In
acute myeloid leukemias (AML), genes encoding PP2A subunits
are generally intact, without apparent somatic mutations or dele-
tions identified to date. One exception is the haploinsufficiency of
the PPP2CA gene encoding the catalytic C subunit in AML cases
with deletions of chromosome 5, including del(5q) specifically
(contribution in this issue by Sallman et al.). The 5q commonly
deleted region also includes several additional tumor suppressor
genes (22), suggesting that haploinsufficiency of PPP2CA may
cooperate with other gene deletions in AML.
Analysis of PP2A subunits and genetic mutations have until
now focused at the level of genetic alteration and post-translational
modifications. The correlation of these mutations with protein
levels in AML cells of abnormal PP2A components has yet to
be determined. In order to understand the expression of PP2A
subunits in human AML, we analyzed transcriptome data col-
lected as part of the Cancer Genome Atlas (TCGA) from 138
patients with AML and 5 healthy controls (23). Raw sequences
were aligned to the hg19 human reference genome using STAR
(24) and differential expression analysis was determined using
DESeq2 Bioconductor package (25). As can be seen in Figure 1,
most genes encoding PP2A subunits do not have statistically signif-
icantly altered expression in AML cells relative to normal CD34+
bone marrow precursor cells. We find that PPP2R1B, encoding
the Aβ scaffold subunit, is significantly down-regulated in AML
cells (Benjamini Hochberg-adjusted p= 0.036). This analysis also
reveals the relative overexpression of genes encoding two regula-
tory B subunits in AML cells, PPP2R2B and PPP2R5B (Benjamini
Hochberg-adjusted p= 0.0025 and 0.00021, respectively). Genes
encoding regulatory B subunits PPP2R2C and PPP2R3B were
found to be minimally expressed in AML cells in this analysis.
In addition, PPP2CA encoding one of the catalytic C subunits
is distinctly down-regulated in patients with TP53 mutant AML,
consistent with cytogenetically complex karyotypes in this disease
subset, and with prior observations of its loss in del(5q) AML (26).
We did not find any other apparent associations between PP2A
subunit gene expression and molecular subtypes of AML in this
FIGURE 1 | Human acute myeloid leukemia cells exhibit distinct
alterations in the expression of specific genes encoding PP2A
subunits. Relative expression of genes encoding PP2A subunits (catalytic
C subunits in red, scaffold A subunits in blue, and regulatory B subunits in
black) measured as a ratio of expression in AML cells relative to normal
CD34+ bone marrow hematopoietic progenitor cells in normalized read
counts. PPP2R2C and PPP2R3B are not significantly expressed and thus
not shown, whereas PPP2R1B, PPP2R2B, and PPP2R5B are statistically
significantly altered in their expression in AML cells relative to normal
CD34+ cells (Benjamini Hochberg-adjusted p<0.05).
analysis. Combined with the analysis of the expression of PP2A
subunits in normal hematopoietic cells (contribution in this issue
by Haesen et al.), these findings indicate that AML cells express
a distinct repertoire of PP2A enzymes, characterized by down-
regulation of scaffold A subunits and up-regulation of specific
regulatory B subunits.
FUNCTIONAL PP2A INACTIVATION
In addition to the apparent alterations in expression of PP2A enzy-
matic subunits, PP2A activity can be dysregulated through func-
tional mechanisms, including post-translational modifications of
the enzymatic C subunit and effects of regulatory proteins that
interact with the A and B subunits. The PP2A catalytic C subunit
is known to undergo phosphorylation and carboxymethylation,
both of which have been found to regulate its enzymatic activity
in the context of active holo-enzyme. Several oncogenic kinases,
including BCR–ABL1 in myeloid leukemias, phosphorylate T304
and T307 of the C subunit, leading to reduced PP2A phosphatase
activity (27, 28). Carboxymethylation of L309 of the C subunit by
the methylesterases LCMT1 and PME-1 leads to altered recruit-
ment of regulatory B55 subunits (29). Finally, oxidative nitration
of Y289 of the B56δ subunit was recently described to interfere with
the assembly of the PP2A holo-enzyme, leading to dysregulation of
BCL-2 phosphorylation and aberrant cell survival in lymphoblas-
tic leukemia and lymphoma cells (30). In summary, PP2A activity
appears to be controlled by two non-mutually exclusive mecha-
nisms: (i) allosteric regulation of the phosphatase activity, and (ii)
regulation of holo-enzyme assembly and recruitment of specific
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substrates by the A and B subunits. These two mechanisms inform
possible pharmacological strategies for therapeutic re-activation
of PP2A, as discussed below.
In addition to regulatory post-translational modifications of
PP2A, several endogenous cellular factors have been found to
inhibit PP2A activity, including CIP2A and SET. Overexpression
of these cellular inhibitors of PP2A leads to functional inactiva-
tion of the PP2A phosphatase activity, and contributes to cellular
transformation. For example, CIP2A appears to transform cells by
direct interaction with the c-Myc transcription factor and inter-
fering with substrate recruitment by PP2A B subunits. In colon
and head and neck squamous cell carcinomas, overexpression of
CIP2A leads to the potentiation of MYC S62 phosphorylation,
the PP2A target, thereby inhibiting proteolysis and resulting in
increased oncogenic MYC protein stability (31, 32). Overexpres-
sion of CIP2A is also associated with increased phosphorylation of
other PP2A substrates, including AKT1, MEK1, and MDM2, pre-
sumably due to interference with the assembly of additional PP2A
holo-enzyme complexes targeting a variety of substrates (33).
Another well-characterized cellular inhibitor of PP2A is SET,
and its regulator SETBP1. Although the exact mechanism is not
well understood, SET is thought to inhibit PP2A by direct bind-
ing to the PP2A catalytic subunit (34). SET is overexpressed in
breast carcinoma and acute leukemia cells, and can directly bind
to the PP2A catalytic C subunit, causing reduced dephosphoryla-
tion of PP2A substrates (35). In AML, SET activity is regulated by
proteolysis, mediated by its binding partner SETBP1, leading to
the formation of an inhibitory SETBP1–SET–PP2A complex (36).
When SETBP1 is overexpressed, SET is stabilized and protected
from protease cleavage and facilitates PP2A inhibition, poten-
tially explaining the relatively poor prognosis in patients with
AML with altered expression of these regulatory proteins (37). In
addition, some patients with AML exhibit SETBP1 overexpression
due to the t(12;18)(p13;q12) chromosomal translocation (36), and
patients with atypical CML can have recurrent G870S mutations
of SETBP1 (38).
THERAPEUTIC STRATEGIES TO REACTIVATE PP2A
Absence of genetic mutations that cause complete loss-of-function
of PP2A phosphatase activity, such as homozygous deletions of
the C or A subunits and their genetic redundancy with two genes
encoding these subunits, makes it possible to potentially reactivate
PP2A for anti-cancer therapy. Such therapeutic PP2A re-activation
strategies can be classified in two non-mutually exclusive mecha-
nisms: (i) allosteric activation of the phosphatase activity, and (ii)
stabilization of active holo-enzyme assembly and displacement of
negative regulatory factors from A and B subunits. The C phos-
phatase subunit is known to be regulated by post-translational
modifications of its C-terminal TPDYFL tail, including nitration
of Y289, phosphorylation of T304 and Y307, and carboxymethy-
lation of L309, which can potentially regulate the allosteric relay
of the structurally juxtaposed 120–126 helix and 183–195 loop
switches regulating the phosphatase catalytic site (39). Indeed,
inhibition of PP2A by carcinogenic antibiotics such as okadaic
acid and microcystin, involves changes in the allosteric regula-
tion of the PP2A catalytic subunit (40). This raises the possibility
that either natural products or small molecules can be used to
pharmacologically modulate the PP2A C subunit to allosterically
activate its phosphatase activity in the context of an active holo-
enzyme (mechanism I). Indeed, forskolin, a diterpene antibiotic,
can reduce the phosphorylation of the C-terminal tail PP2A C
subunit Y307, leading to PP2A activation (41, 42). This effect
appears to be independent of forskolin’s activation of adenylate
cyclase, as evidenced by the apparently equal anti-leukemic efficacy
of 1,9-dideoxy-forskolin, which does not alter cyclic AMP levels.
Consistent with this, forskolin treatment was found to be synergis-
tic with cytotoxic AML chemotherapeutic agents, idarubicin and
cytarabine (41).
Fingolimod or FTY720, a derivative of the antibiotic myriocin,
activates PP2A in part by inhibition of the negative PP2A regulator
SET (mechanism II). Fingolimod can bind SET directly, causing
its displacement from and assembly of active PP2A holo-enzymes
(43). Treatment of AML cells with fingolimod leads to dephos-
phorylation of PP2A substrates, such as the KIT receptor, AKT1,
and STAT5, causing cell death (44, 45). Because fingolimod also
inhibits sphingosine kinase 1, current efforts are focused on using
fingolimod derivatives that lack this activity, such as (R)-FTY720-
OMe and OSU-2S to specifically activate PP2A (46). Similarly, the
cell-penetrating peptide OP449 or COG449 is an apolipoprotein
E-mimetic that directly binds SET, relieving SET-mediated PP2A
phosphatase inhibition (47, 48).
Recently, perphenazine and related phenothiazines were found
to activate PP2A, causing dephosphorylation of PP2A substrates
and leukemia cell death (49). Perphenazine can bind directly to
the PP2A Aα scaffold subunit (49). This can cause PP2A acti-
vation either due to the displacement of a negative A subunit
regulator, such as CIP2A (31), and/or allosteric effects of the C
subunit activity when bound to the A scaffold HEAT domains
11–15. This mechanism may also explain the pervasive inhibition
of serine/threonine kinase signaling by the chemically related tri-
fluoperazine drugs (50). Elucidation of the structural basis and
effects on PP2A holo-enzyme assembly and phosphatase activ-
ity should lead to the development of more potent and specific
phenothiazine-like PP2A activators.
FUTURE THERAPEUTIC STRATEGIES
Cellular PP2A comprises an ensemble of distinct holo-enzymes
associated with specific regulatory subunits. Cancer cells with
non-genetic mechanisms of PP2A inactivation, such as altered
expression of genes encoding PP2A subunits or aberrant expres-
sion of PP2A negative regulators, may therefore be candidates for
pharmacological functional re-activation of PP2A for anti-cancer
therapy. In AML specifically, PP2A phosphatase activity appears
to be dysregulated as a result of reduced expression of specific A
scaffold subunits, and altered expression of regulatory B subunits.
Consequently, leukemogenic effects of PP2A dysregulation are
mediated by specific phospho-serine and phospho-threonine sub-
strates. Likewise, pharmacological strategies for therapeutic PP2A
re-activation will depend on the specific details of PP2A dysregula-
tion. For example, pharmacologic inhibitors of PP2A negative reg-
ulator SET, such as fingolimod, OP449 and its analogs, will likely be
ineffective in leukemias without SET overexpression or activation.
In contrast, pharmacological PP2A activators that modulate PP2A
phosphatase activity through allosteric regulation of phosphatase
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activity, such as forskolin and possibly perphenazine and related
drugs, may have broader efficacy. Finally, detailed understanding
of the molecular mediators of carcinogenic PP2A dysregulation,
including specific substrates and signaling pathways, will be nec-
essary to define not only biomarkers that can be used to prospec-
tively identify susceptible tumors but also to determine effective
combination therapies.
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